Denosumab increases BMD more than zoledronic acid in women who were treated with bisphosphonates.
Many express a preference for weekly or monthly oral bisphosphonate regimens.
Oral bisphosphonates appear to lower the risk for subsequent fracture and mortality after fracture.
Patients with type 2 diabetes may be at higher risk for fracture than indicated by FRAX score.
Many older people unconcerned about or unaware of osteoporosis.
Asian women taking bisphosphonates may have a higher risk for atypical femur fracture than white women.
Treatment improved bone balance and reduced bone turnover.
The sclerostin inhibitor may increase bone strength at the spine and hip in postmenopausal women.
Treatment over 5 years appears to be safe and effective.
Variables included gender and age.
Selective oral cathepsin K inhibitor odanacatib improved bone density in older women with osteoporosis.
PTH (1-84) for 7 years is linked to reduced calcium and calcitriol supplementation.
Denosumab treatment for up to 10 years is linked to persistent reduction in bone turnover and increased BMD.
Higher doses of vitamin D may actually do more harm than good in elderly women.
Three or more cups per day may lower risk for fracture.
Fracture risk may be lower with bisphosphonates in women with diabetes.
Fracture risk may be significantly lower in postmenopausal women with abaloparatide vs. teriparatide or placebo.
While these may serve as predictors, bone mineral density may not.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation